Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from Latin American patients with a diagnosis of pneumonia: Results from the SENTRY antimicrobial surveillance program (1998)

Diagnostic Microbiology and Infectious Disease

Volumn 37, Issue 1, 2000, Pages 63-74

  Lewis, M Todd ^a   Gales, Ana C ^a   Sader, Helio S ^a   Pfaller, Michael A ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Antimicrobial therapy; Multiply resistant organisms; Pneumonia; Ribotyping; SENTRY; Surveillance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; CLINDAMYCIN; GATIFLOXACIN; GENTAMICIN; GREPAFLOXACIN; IMIPENEM; LINCOSAMIDE; MEROPENEM; OFLOXACIN; OXACILLIN; PIPERACILLIN; TEICOPLANIN; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; ENTEROBACTER; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PNEUMONIA; PRIORITY JOURNAL; RIBOTYPING; SOUTH AND CENTRAL AMERICA; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIA; HUMANS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; POPULATION SURVEILLANCE;

EID: 0034008792     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(00)00123-1     Document Type: Article

References (38)

1. Anonymous. (1997). Guidelines for prevention of nosocomial pneumoniae. Centers for Disease Control and Prevention. Morbid Mortal Wkly Rep 46, 1-79.
2. Barry A.I., Fuchs P.C., Brown S.D. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin). Antimicrob Agents Chemother. 42:1998;945-946.
3. Bauernfeind A., Casellas J.M., Goldberg M., Holley M., Jungwirth R., Mangold P., Rohnisch T., Schweighart S., Wilhelm R. A new plasmidic cefotaximase from patients infected with Salmonella typhimurium. Infection. 20:1992;158-163.
4. Burns J.L., Wadsworth C.D., Barry J.L., Goodall C.P. Nucleotide sequence analysis of a gene from Burkholderia cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. Antimicrob Agents Chemother. 40:1996;307-313.
5. Bush K., Jacoby G.A., Medeiros A.A. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 39:1995;1211-1233.
6. Cartwright S.J., Waley S.G. Purification of β-lactamases by affinity chromatography on phenyllboronic acid-agarose. Biochemical J. 221:1984;505-512.
7. Cormican M.G., Marshall S.A., Jones R.N. Detection of extended-spectrum β-lactamase (ESBL)-producing strains by Etest ESBL screen. J Clin Microbiol. 34:1996;1880-1884.
8. Dixon R.E. Economic cost of RTI in the U.S. Am J Med. 78:(6B):1985;45-51.
9. Doern G.V., Jones R.N., Gerlach E.H., Washington J.A., Biedenbach D.J., Brueggemann A., Erwin M.E., Knapp C., Raymond J. Multicenter clinical laboratory evaluation of a β-lactamase disk assay employing a novel chromogenic cephalosporin, S1. J Clin Microbiol. 33:1995;1665-1667.
10. Gales, A. C., Jones, R. N., Pfaller, M. A., Sader, H. S., & SENTRY Study Group. (2000). A two year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: Results from the SENTRY Antimicrobial Surveillance Program. IJID (in press).
11. Hancock R.E.W., Bellido F. Antibacterial in vitro activity of fourth generation cephalosporins. J Chemother. 7:(suppl. 5):1995;29-34.
12. Hancock, R. E. W. (1998). Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative Gram-negative bacteria. Clin Infect Dis 27(suppl. 1), S93-S99.
13. Jones R.N. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med. 100:(suppl. 6A):1996;3S-12S.
14. Jones R.N. Can antimicrobial activity be sustained? An appraisal of orally administered drugs used for respiratory tract infections. Diagn Microbiol Infect Dis. 27:1997;21-28.
15. Jones, R. N., Kugler, K. C., Erwin, M. E., Biedenbach, D. J., Beach, M. L., Pfaller, M. A., & The Quality Control Study Group. (1998). Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-μg) diffusion methods. Diagn Microbiol Infect Dis 33, 247-253.
16. Lynch J.P., Niederman M.S. Controversies in respiratory infection. Semin Respir Infect. 12:1997;269-270.
17. Mandell L.A., Campbell G.D. Jr. Nosocomial pneumonia guidelines. An international perspective. Chest. 113:1998;118S-193S.
18. Marrie T.J. Community acquired pneumonia Epidemiology, etiology and treatment. Infect Dis Clin NA. 12:1998;723-740.
19. Martson B.J., Plouffe J.F., File T.M. Jr, Hackman B.A., Salstrom S.J., Lipman H.B., Kolczak M.S., Breiman R.F. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia incidence Study Group. Arch Intern Med. 157:1997;1709-1718.
20. McEachern, R. & Campbell, D. G. Jr. Hospital-acquired pneumonia: Epidemiology, etiology, and treatment. Infect Dis Clin NA 12, 761-779.
21. Mett H., Rosta S., Schacher B., Frei R. Outer membrane permeability and β-lactamase content in Pseudomonas maltophilia. Rev Infect Dis. 10:1988;765-769.
22. National Center of Health Statistics. (1992). National hospital discharge survey: Annual summation, 1990. Vital Health Stat 13, 1-225.
23. National Committee for Clinical Laboratory Standards (NCCLS). (1997). Standard methods for antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. Wayne, PA: NCCLS.
24. National Committee for Clinical Laboratory Standards (NCCLS). (1999). Performance standards for antimicrobial susceptibility testing: Ninth informational supplement M100-S9. Wayne, PA: NCCLS.
25. Parr, T., Moore, R. A., Moore, L., & Hancock, R. E. W. (1987). Role of porin in intrinsic resistance of Pseudomonas cepacia. Antimicrob Agents Chemother 31, 121-123.
26. Pfaller, M. A., Jones, R. N., Doern, G. V., Kugler K., & The SENTRY Participants Group. (1998). Bacterial pathogens isolated from patients with blood stream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother 42, 1762-1770.
27. Pfaller M.A., Wendt C., Hollis R.J. Comparative evaluation of an automated ribotyping system versus pulsed-field gel electrophoresis for epidemiological typing of clinical isolates of Escherichia coli and Pseudomonas aeruginosa from patients with recurrent Gram-negative bacteremia. Diagn Microbiol Infect Dis. 25:1996;1-8.
28. Poole, K., Krebes, K., McNally, C., & Neshat, S. (1993). Multiple antibiotic resistance in Pseudomonas aeruginosa: Evidence for involvement of an efflux operon. J Bacteriol 175, 7363-7672.
29. Proecnca R., Niu W.W., Cacalano G., Prince A. The Pseudomonas cepacia 249 chromosomal penicillinase is a member of the amp C family of chromosomal penicillinases. Antimicrob Agents Chemother. 37:1993;667-674.
30. Quinn J.P., Studemeister A.E., DiVicenzo C.A., Lerver S.A. Resistance to imipenem in Pseudomonas aeruginosa: Clinical experience and biochemical mechanisms. Rev Infect Dis. 10:1988;892-898.
31. Sader, H. S., Jones, R. N., Gales, A. C., Winokur, P., Kugler, K. C., Pfaller, M. A., Doern, G. V., & the SENTRY Latin American Study Group. (1997). Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: Analysis of results from the SENTRY Antimicrobial Surveillance Program Diagn Microbiol Infect Dis 32, 289-301.
32. Sader H.S., Pignatari A.C., Hollis R.J., Leme I., Jones R.N. Oxacillin and quinolone-resistant Staphylococcus aureus in Sao Paulo, Brazil A multicenter molecular epidemiology study. Infect Control Hosp Epi. 14:1993;260-264.
33. Sanders, C. C. (1989). The chromosomal β-lactamases. In LE Bryan, (Ed). Microbiol Resistance to Drugs. Handbook of Experimental Pharmacology. Vol 91. pp. 129-149. Berlin: Springer-Verlag.
34. Sato K., Nakae T. Outer membrane permeability of Acinetobacter calcoaceticus and its implication in antibiotic resistance. J Antimicrob Chemother. 28:1991;35-45.
35. Spencer R.C. Predominant pathogens found in the European prevalence of infection in intensive care study. Eur J Clin Microbiol Infect Dis. 15:1996;281-284.
36. Torres A., Aznar R., Gatell J.M., Jimenez P., Gonzales J. Incidence, risk and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am J Respir Crit Care Med. 157:1990;523-528.
37. Vincent J.L., Bihari D.J., Sute P.M., Bruining H.A., White J. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intenoved care (EPIC) study. EPIC International Advisory Committee. JAMA. 274:1995;636-644.
38. Yamakazi, E., Ishic, J., Sato, K., & Nakae T. (1989). The barrier function of the outer membrane of Pseudomonas maltophilia in the diffusion of saccharides and β-lactam antibiotics. FEMS Microbiol Lett 60, 85-88.